Ethinylestradiol/segesterone acetate

Ethinylestradiol/segesterone acetate (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains ethinylestradiol, an estrogen, and segesterone acetate, a progestin.[1] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][2]

Ethinylestradiol /
segesterone acetate
Combination of
EthinylestradiolEstrogen
Segesterone acetateProgestogen
Clinical data
Trade namesAnnovera
Other namesEE/SGA; EE/SA
Routes of
administration		Vaginal ring
Identifiers
KEGG

Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for 7 days, during which the user experiences a period (withdrawal bleeding.) This can be repeated 13 times, for one full year of use.[3] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed to a patient and can be stored at temperatures up to 30 degrees Celsius.[4]

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for use in the United States on 10 August 2018.[2]

See also

References
  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
  2. https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-fda-approval-annoveratm-segesterone
  3. "FDA approves new vaginal ring for one year of birth control".
  4. "FDA prescribing information for Annovera" (PDF).



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.